Literature DB >> 10155611

Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America.

K Clemens1, R Townsend, F Luscombe, J Mauskopf, J Osterhaus, J Bobula.   

Abstract

In January 1995, the Pharmaceutical Research and Manufacturers of America (PhRMA) adopted a voluntary set of principles to provide guidance for its member companies on the conduct and evaluation of pharmacoeconomic research. The principles were prepared by a working group of pharmacoeconomic scientists from the PhRMA Task Force on the Economic Evaluation of Pharmaceuticals. The principles were reviewed by a panel of academic experts and outside reviewers at each stage of their development. The PhRMA document consists of a set of broad principles that will foster high quality pharmacoeconomic research without impeding further methodological development of the field. Specific recommendations are offered in those methodological areas for which general agreement exists. However, no attempt was made to force a consensus for those methodological issues which have yet to be resolved. The principles address methodology and reporting of research rather than sponsor-investigator relationships or conflict of interest issues, which have been addressed elsewhere. This approach is based on the belief that the scientific integrity of pharmacoeconomic research is best ensured through the soundness of the research methods used and the full disclosure and transparency of all methods, analyses and results.

Mesh:

Year:  1995        PMID: 10155611     DOI: 10.2165/00019053-199508020-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  19 in total

1.  The Australian Guidelines for subsidisation of pharmaceuticals: the road to cost-effective drug prescribing?

Authors:  M Johannesson
Journal:  Pharmacoeconomics       Date:  1992-11       Impact factor: 4.981

2.  Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.

Authors:  B R Luce
Journal:  Pharmacoeconomics       Date:  1993-01       Impact factor: 4.981

3.  Economic evaluation of drug therapy: a review of the contingent valuation method.

Authors:  M Johannesson; P O Johansson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

4.  Economic evaluation of pharmaceuticals: science or marketing?

Authors:  M F Drummond
Journal:  Pharmacoeconomics       Date:  1992-01       Impact factor: 4.981

Review 5.  The design of future cost-benefit studies.

Authors:  A Maynard
Journal:  Am Heart J       Date:  1990-03       Impact factor: 4.749

Review 6.  Meta-analysis in medicine. Where we are and where we want to go.

Authors:  M Jenicek
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

7.  The journal's policy on cost-effectiveness analyses.

Authors:  J P Kassirer; M Angell
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

Review 8.  Clinical economics. A guide to the economic analysis of clinical practices.

Authors:  J M Eisenberg
Journal:  JAMA       Date:  1989-11-24       Impact factor: 56.272

Review 9.  Meta-analysis of correlates of provider behavior in medical encounters.

Authors:  J A Hall; D L Roter; N R Katz
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

Review 10.  Meta-analysis. A quantitative approach to research integration.

Authors:  S B Thacker
Journal:  JAMA       Date:  1988-03-18       Impact factor: 56.272

View more
  23 in total

Review 1.  Design, analysis and presentation of multinational economic studies: the need for guidance.

Authors:  Francis Pang
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

3.  Reporting format for economic evaluation. Part I: Application to the Dutch healthcare system.

Authors:  M J Nuijten; M J Brorens; Y A Hekster; A van der Kuy; J H Lockefeer; P A de Smet; G Bonsel; M H Pronk
Journal:  Pharmacoeconomics       Date:  1998-08       Impact factor: 4.981

Review 4.  The selection of data sources for use in modelling studies.

Authors:  M J Nuijten
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

5.  Applied pharmacoeconomics. When can publication be legitimately withheld?

Authors:  G C Yee; A L Hillman
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

6.  Pharmacoeconomics in the new millennium. A pharmaceutical industry perspective.

Authors:  R Thwaites; R J Townsend
Journal:  Pharmacoeconomics       Date:  1998-02       Impact factor: 4.981

Review 7.  Why training is the key to successful guideline implementation.

Authors:  A D Paltiel; P J Neumann
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

8.  Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations.

Authors:  Mark J C Nuijten
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

9.  A case for the adoption of pharmacoeconomic guidelines in Japan.

Authors:  S Ikeda; N Ikegami; A J Oliver; M Ikeda
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

10.  Pharmacoeconomics and formulary decision making.

Authors:  L A Sanchez
Journal:  Pharmacoeconomics       Date:  1996       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.